Trial site
Norton Cancer Institute
- 62running trials
- 46closed trials
The trials here
What the 109 trials at this site are about, from their registry records.
- Conditions
- Lung cancer23 trials
- Head and neck cancer14 trials
- Multiple myeloma13 trials
- Follicular lymphoma11 trials
- Colorectal cancer10 trials
- Diffuse large B-cell lymphoma9 trials
- Prostate cancer9 trials
- Bladder cancer8 trials
- Gastric and oesophageal cancer8 trials
- Mantle cell lymphoma8 trials
- Melanoma8 trials
- Ovarian cancer8 trials
- and 19 more
- Phase
- Phase 343 trials
- Phase 1/220 trials
- Phase 118 trials
- Phase 218 trials
- Phase 2/34 trials
- Status
- Active, not recruiting34 trials
- Completed31 trials
- Recruiting25 trials
- Terminated14 trials
- Not yet recruiting2 trials
- Enrolling by invitation1 trial
- Suspended1 trial
- Withdrawn1 trial
- Lead sponsor
- Janssen Research & Development, LLC15 trials
- Regeneron Pharmaceuticals6 trials
- Allogene Therapeutics3 trials
- Amgen3 trials
- Astellas Pharma Global Development, Inc.3 trials
- and 62 more
Running trials
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer
Active, not recruiting
Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Recruiting
Active, not recruiting
Recruiting
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Recruiting
Recruiting
Enrolling by invitation
Active, not recruiting
Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells
Active, not recruiting
Recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Recruiting
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Active, not recruiting
Recruiting
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
Active, not recruiting
Active, not recruiting
Showing 50 of 62.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer6 recruiting
- Multiple myeloma6 recruiting
- Head and neck cancer4 recruiting
- Diffuse large B-cell lymphoma3 recruiting
- Gastric and oesophageal cancer3 recruiting
- Prostate cancer3 recruiting
- Acute myeloid leukaemia2 recruiting
- Childhood cancers2 recruiting
- Colorectal cancer2 recruiting
- Follicular lymphoma2 recruiting
- Liver and biliary tract cancer2 recruiting
- Mantle cell lymphoma2 recruiting
- Myelodysplastic syndromes2 recruiting
- Ovarian cancer2 recruiting
- Acute lymphoblastic leukaemia1 recruiting
- Bladder cancer1 recruiting
- Brain metastases1 recruiting
- Cervical cancer1 recruiting
- Chronic lymphocytic leukaemia1 recruiting
- Endometrial cancer1 recruiting
- Glioblastoma1 recruiting
- Hodgkin lymphoma1 recruiting
- Kidney cancer1 recruiting
- Melanoma1 recruiting
- Meningioma1 recruiting
- Metastatic breast cancer1 recruiting
- Myeloproliferative neoplasms1 recruiting
- Pancreatic cancer1 recruiting
- Triple-negative breast cancer1 recruiting
Closed trials
Recruiting
Terminated
Terminated
A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers
Terminated
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
Terminated
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
Withdrawn
Completed
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Terminated
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
Completed
Terminated
Recruiting
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Terminated
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Terminated
Completed
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Completed
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
Terminated
Recruiting
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Completed
Completed
Terminated
Completed
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
Completed
The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Completed
Completed
Completed
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
Completed
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Completed
Terminated
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Terminated
Completed
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Completed
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
Completed
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
Completed
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Completed
Completed
Completed
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Completed
Site data: ClinicalTrials.govUpdated 18 Nov 2026